Basic pharmacology of generalized anxiety disorder

Robert Nisticò, Ferdinando Nicoletti, Dalila Mango, Chiara Schepisi

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Generalized anxiety disorder (GAD) is a chronic, disabling condition in which treatment response is often unsatisfactory. Aetiology and underlying mechanisms of GAD, as for most psychiatric disorders, remain relatively poorly understood. Preclinical research has expanded substantially in the past decade and contributed to the identification of a growing range of pharmacological targets for reducing the burden of GAD. In this chapter we describe some of the more widely used approaches for understanding the neurobiology of anxiety disorders as well as evaluating anxiolytic activity of known and potential therapeutic agents. In addition, we will focus on neurotransmitter systems implicated in generating and sustaining anxiety including the GABA, serotonin, glutamate, endocannabinoids, and neuropeptide systems. The major challenge in effective anxiolytic drug discovery is the selective targeting of receptor sub-types in anxietyrelated brain circuits.

Original languageEnglish
Title of host publicationNew Perspectives on Generalized Anxiety Disorder
PublisherNova Science Publishers, Inc.
Pages69-82
Number of pages14
ISBN (Print)9781633215320, 9781629480367
Publication statusPublished - Jul 1 2014

Fingerprint

Anxiety Disorders
Pharmacology
Anti-Anxiety Agents
Endocannabinoids
Neurobiology
Drug Discovery
Neuropeptides
gamma-Aminobutyric Acid
Neurotransmitter Agents
Psychiatry
Glutamic Acid
Serotonin
Anxiety
Brain
Research
Therapeutics

ASJC Scopus subject areas

  • Psychology(all)

Cite this

Nisticò, R., Nicoletti, F., Mango, D., & Schepisi, C. (2014). Basic pharmacology of generalized anxiety disorder. In New Perspectives on Generalized Anxiety Disorder (pp. 69-82). Nova Science Publishers, Inc..

Basic pharmacology of generalized anxiety disorder. / Nisticò, Robert; Nicoletti, Ferdinando; Mango, Dalila; Schepisi, Chiara.

New Perspectives on Generalized Anxiety Disorder. Nova Science Publishers, Inc., 2014. p. 69-82.

Research output: Chapter in Book/Report/Conference proceedingChapter

Nisticò, R, Nicoletti, F, Mango, D & Schepisi, C 2014, Basic pharmacology of generalized anxiety disorder. in New Perspectives on Generalized Anxiety Disorder. Nova Science Publishers, Inc., pp. 69-82.
Nisticò R, Nicoletti F, Mango D, Schepisi C. Basic pharmacology of generalized anxiety disorder. In New Perspectives on Generalized Anxiety Disorder. Nova Science Publishers, Inc. 2014. p. 69-82
Nisticò, Robert ; Nicoletti, Ferdinando ; Mango, Dalila ; Schepisi, Chiara. / Basic pharmacology of generalized anxiety disorder. New Perspectives on Generalized Anxiety Disorder. Nova Science Publishers, Inc., 2014. pp. 69-82
@inbook{7c08a93d232f460fa6959d152781d780,
title = "Basic pharmacology of generalized anxiety disorder",
abstract = "Generalized anxiety disorder (GAD) is a chronic, disabling condition in which treatment response is often unsatisfactory. Aetiology and underlying mechanisms of GAD, as for most psychiatric disorders, remain relatively poorly understood. Preclinical research has expanded substantially in the past decade and contributed to the identification of a growing range of pharmacological targets for reducing the burden of GAD. In this chapter we describe some of the more widely used approaches for understanding the neurobiology of anxiety disorders as well as evaluating anxiolytic activity of known and potential therapeutic agents. In addition, we will focus on neurotransmitter systems implicated in generating and sustaining anxiety including the GABA, serotonin, glutamate, endocannabinoids, and neuropeptide systems. The major challenge in effective anxiolytic drug discovery is the selective targeting of receptor sub-types in anxietyrelated brain circuits.",
author = "Robert Nistic{\`o} and Ferdinando Nicoletti and Dalila Mango and Chiara Schepisi",
year = "2014",
month = "7",
day = "1",
language = "English",
isbn = "9781633215320",
pages = "69--82",
booktitle = "New Perspectives on Generalized Anxiety Disorder",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Basic pharmacology of generalized anxiety disorder

AU - Nisticò, Robert

AU - Nicoletti, Ferdinando

AU - Mango, Dalila

AU - Schepisi, Chiara

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Generalized anxiety disorder (GAD) is a chronic, disabling condition in which treatment response is often unsatisfactory. Aetiology and underlying mechanisms of GAD, as for most psychiatric disorders, remain relatively poorly understood. Preclinical research has expanded substantially in the past decade and contributed to the identification of a growing range of pharmacological targets for reducing the burden of GAD. In this chapter we describe some of the more widely used approaches for understanding the neurobiology of anxiety disorders as well as evaluating anxiolytic activity of known and potential therapeutic agents. In addition, we will focus on neurotransmitter systems implicated in generating and sustaining anxiety including the GABA, serotonin, glutamate, endocannabinoids, and neuropeptide systems. The major challenge in effective anxiolytic drug discovery is the selective targeting of receptor sub-types in anxietyrelated brain circuits.

AB - Generalized anxiety disorder (GAD) is a chronic, disabling condition in which treatment response is often unsatisfactory. Aetiology and underlying mechanisms of GAD, as for most psychiatric disorders, remain relatively poorly understood. Preclinical research has expanded substantially in the past decade and contributed to the identification of a growing range of pharmacological targets for reducing the burden of GAD. In this chapter we describe some of the more widely used approaches for understanding the neurobiology of anxiety disorders as well as evaluating anxiolytic activity of known and potential therapeutic agents. In addition, we will focus on neurotransmitter systems implicated in generating and sustaining anxiety including the GABA, serotonin, glutamate, endocannabinoids, and neuropeptide systems. The major challenge in effective anxiolytic drug discovery is the selective targeting of receptor sub-types in anxietyrelated brain circuits.

UR - http://www.scopus.com/inward/record.url?scp=84955156071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955156071&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84955156071

SN - 9781633215320

SN - 9781629480367

SP - 69

EP - 82

BT - New Perspectives on Generalized Anxiety Disorder

PB - Nova Science Publishers, Inc.

ER -